Biomay AG, a fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria, has announced the expansion of its biomanufacturing facility located in Vienna’s 9th district. The upgraded site will serve as the company’s Center of Excellence for end-to-end mRNA (messenger RNA) manufacturing services, featuring five GMP-commissioned clean rooms for upstream and downstream processing, as well as aseptic filling of mRNA drug product.
The expanded facility is home to a seven-glove isolator with an automated processing line for aseptic filling, vial capping, and crimping, primarily serving clinical-stage investigational medicinal products (IMPs). Biomay has also gained significant experience in GMP production of linear DNA templates, notably supplying large quantities of these templates during the COVID-19 pandemic for the manufacturing of a COVID-19 mRNA vaccine.
Dr. Angela Neubauer, the Site Head of the facility and Biomay’s Senior Vice President of Client Business, said: “Biomay is evolving from being a drug substance and API manufacturer to offering drug product aseptic filling, testing and release services. Our strategic goal is to establish ourselves as a leading player in the mRNA CDMO field, alongside our existing expertise in proteins and plasmids.”
Founded in 1984, Biomay AG operates a 4000 sqm main site in Vienna’s 22nd district, as well as the newly expanded 2000 sqm integrated biomanufacturing facility in Vienna’s 9th district. The company specializes in GMP services for the manufacturing of therapeutic proteins, plasmid DNA and mRNA.
